The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02• GutAlive®: Microbiota Collection and Transport in Anaerobic Conditions• From Discovery to Disease Prevention: How the Biose–Siolta Partnership is Advancing a New Generation of Live Biotherapeutics• A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation•

Microbiome Times

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection
Clinical & Manufacturing

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

JAN 24, 2022
Viruses and game theory
Pharma & Human Health

Viruses and game theory

JAN 13, 2022
Researchers discover new hiding place for antibiotic resistance
Infectious Disease & AMR

Researchers discover new hiding place for antibiotic resistance

DEC 20, 2021
SGS Acquisition of Quay Pharma Will Further Strengthen Offering
Finance

SGS Acquisition of Quay Pharma Will Further Strengthen Offering

DEC 16, 2021
Food for Health: A new direction for American Agriculture
Editor's Choice

Food for Health: A new direction for American Agriculture

DEC 14, 2021
EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic
Finance

EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic

DEC 13, 2021
CRISPRing the microbiome is just around the corner
Editor's Choice

CRISPRing the microbiome is just around the corner

DEC 10, 2021
Bringing the Transformative Power of Synthetic Biology to Medicine
Biotech Showcase

Bringing the Transformative Power of Synthetic Biology to Medicine

DEC 6, 2021
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD
Clinical & Manufacturing

Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD

DEC 6, 2021
Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome
Editor's Choice

Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome

DEC 2, 2021
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
Finance

Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy

DEC 2, 2021